-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
October 2022
-
Growing Body of Evidence Highlights Potential Applications for Liquid Biopsy in Clinical Practice
During a lecture at NACLC 22, Dr. Christian Rolfo illustrated how ctDNA could be used to monitor progression and inform treatment decisions.
-
IASLC Leadership Shares Experiences, Offers Advice for Women in Thoracic Oncology
During a networking panel at NACLC 22, CEO Karen Kelly and President Heather Wakelee joined program co-chairs Drs. Jessica Donington, Marina Chiara Garassino, and Jyoti Patel for a discussion with other women in the field.
-
When Perfect is the Enemy of Good: Investigators Compare Rigorous Clinical Trial Data to Real-World Experience
Using a real-world cohort of US veterans, researchers examine the effectiveness of durvalumab consolidation in unresectable stage III NSCLC.
-
Public Interest in Complementary, Alternative Approaches to Smoking Cessation Growing
While evidence is mixed on the efficacy of some non-traditional methods, Dr. Deepti Behl says lung cancer physicians should be familiar with the options and support patients who are willing to try to stop smoking.
-
In Brief for Oct. 26, 2022
Upcoming IASLC meetings offer educational opportunities around the globe. Read more for registration and abstract news from LACLC, ACLC, and TTLC.
-
NACLC 22 Educational Session Explores the Rationale for Immune Checkpoint Inhibition
During IASLC’s North America Conference on Lung Cancer, MD Anderson’s Dr. Tina Cascone reviewed the evidence for neoadjuvant and adjuvant therapy in NSCLC.
-
Researcher Reveals How Air Pollution May Cause Lung Cancer
During ESMO Congress 2022, Prof. Charles Swanton shared data that show cells with EGFR and KRAS gene mutations can turn cancerous when exposed to pollution from the burning of fossil fuels.
-
In Brief for October 12, 2022
Former IASLC board member Dr. Carolyn Dresler recently honored for her lifetime of tobacco control advocacy. Penn Medicine chosen as site for US National Cancer Institute Telehealth Research Center of Excellence.
-
KEYNOTE-604 Follow-Up Results Continue to Show Clinically Meaningful Improvement
Long-term data presented by Dr. Charles Rudin during WCLC 2022 showed significant OS benefit for patients with extensive stage SCLC on pembrolizumab combination versus placebo.
-
Study Shows Shorter-Term Assessments Underestimate Pollution Exposure
During WCLC 22, Dr. Renelle Myers demonstrated the importance of considering long-term cumulative exposure to air pollutants when assessing individual lung cancer risk.